ArticleBMJ open ophthalmology2022
Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII).
Article in BMJ open ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Sterile Caliper Anterior Chamber Decompression Mitigates Intraocular Pressure Spikes in Intravitreal Injections.Translational vision science & technology · 2024Trial
- Article
- Serum Procalcitonin to Support Early Triage for Possible Systemic Infection in Patients with Endophthalmitis.Diagnostics (Basel, Switzerland) · 2026Article
- Adverse Events Reported with Standard-Dose and High-Dose Aflibercept: A FAERS Pharmacovigilance Study.Vision (Basel, Switzerland) · 2026Article
- Patient and Physician Perspectives on the Management of Diabetic Macular Edema.Ophthalmology and therapy · 2026Article
- Comparison of Clinician Review Time and Confidence with Optical Coherence Tomography Digital versus Print-Based Workflows: A Pilot Observer Study.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Six-month comparative outcomes of aflibercept and faricimab in treatment-naïve macular edema secondary to branch retinal vein occlusion.Japanese journal of ophthalmology · 2026Observational
- Administration of the Travoprost Intracameral Implant in an Office-Based Surgery Setting.Ophthalmology and therapy · 2025Article
- A thematic analysis of patients' experiences of receiving treatment for Neovascular age-related macular degeneration (nAMD).Eye (London, England) · 2025Article
- Efficacy of aflibercept combined with 80% dose photodynamic therapy for pachychoroid neovasculopathy.Scientific reports · 2025Article
- Artificial intelligence in managing retinal disease-current concepts and relevant aspects for health care providers.Wiener medizinische Wochenschrift (1946) · 2025Review
- Optic Nerve Head Structural Changes After Intravitreal Injection.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Discordance Among Patients and Ophthalmologists Regarding the Burden of Intravitreal Injections.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- Effective Prediction of Drug Transport in a Partially Liquefied Vitreous Humor: Physics-informed Neural Network Modeling for Irregular Liquefaction Geometry.Engineering applications of artificial intelligence · 2024Article
- Doxorubicin-loaded DNA origami nanostructures: stability in vitreous and their uptake and toxicity in ocular cells.Nanoscale · 2024Article
- Article
- Switching from a Fixed Monthly Aflibercept Regimen to Bi-Monthly Brolucizumab in Refractory Cases of Neovascular Age-Related Macular Degeneration.Journal of clinical medicine · 2024Article
- Review
- Extended Intraocular Drug-Delivery Platforms for the Treatment of Retinal and Choroidal Diseases.Journal of vitreoretinal diseasesReview
- Evaluation of pain scores during intravitreal injection in systemic conditions and in conjunction with medications.Therapeutic advances in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo quantify the areas of burden experienced by patients requiring repeated intravitreal injections (IVI) in the management of exudative retinal diseases.
methodsThe validated Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections survey was administered to patients at four retina clinical practices across four US states. The primary outcome measure was Treatment Burden Score (TBS), a single score assessing overall burden.
resultsOf 1416 (n=657 age-related macular degeneration; n=360 diabetic macular oedema/diabetic retinopathy; n=221 retinal vein occlusion; n=178 other/uncertain) patients, 55% were women with an average age of 70 years. Patients most frequently reported receiving IVI every 4-5 weeks (40%). The mean TBS was 16.1±9.2 (range 1-48; scale of 1-54), and the TBS was higher in patients with diabetic macular oedema and/or diabetic retinopathy (DMO/DR) (17.1) compared with those with age-related macular degeneration (15.5) or retinal venous occlusive (15.3) (p=0.028). Though the mean level of discomfort was quite low (1.86) (scale 0-6), 50% of patients reported experiencing side effects more than half of the visits. Patients having received fewer than 5 IVI reported higher mean anxiety levels before (p=0.026), during (p=0.050) and after (p=0.016) treatment compared with patients having received more than 50 IVI. After the procedure, 42% of patients reported restrictions from usual activities due to discomfort. Patients reported a high mean satisfaction rating of 5.46 (scale 0-6) with the care of their diseases.
conclusionsThe mean TBS was moderate and highest among patients with DMO/DR. Patients with more total injections reported lower levels of discomfort and anxiety but higher disruption to daily life. Despite the challenges related to IVI, the overall satisfaction with treatment remained high.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.